Skip to content
OpenCapital
Get started

Monopar Therapeutics MNPR Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
——
Prime Medicine logo
Prime MedicinePRME
——
Viking Therapeutics logo
Viking TherapeuticsVKTX
——
Tango Therapeutics logo
Tango TherapeuticsTNGX
——

Other financials

Income statement

See full
Revenue-—
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19—

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0×0.0×
Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's available for sale securities debt securities current?
Monopar Therapeutics (MNPR) reported available for sale securities debt securities current of $52.37M in Q1 2026.
How has Monopar Therapeutics's available for sale securities debt securities current changed year-over-year?
Monopar Therapeutics's available for sale securities debt securities current increased by 32.5% year-over-year, from $39.51M to $52.37M.
What is the long-term trend for Monopar Therapeutics's available for sale securities debt securities current?
Over 3 years (2022 to 2025), Monopar Therapeutics's available for sale securities debt securities current has grown at a 71.0% compound annual growth rate (CAGR), from $12.18M to $60.88M.